1286748-45-5Relevant academic research and scientific papers
Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
Dong, Qing,Dougan, Douglas R.,Gong, Xianchang,Halkowycz, Petro,Jin, Bohan,Kanouni, Toufike,O'Connell, Shawn M.,Scorah, Nicholas,Shi, Lihong,Wallace, Michael B.,Zhou, Feng
, p. 1315 - 1319 (2011/04/16)
A novel 5-phenylamino-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione series of MEK inhibitors has been developed using structure-based drug design. Lead optimization of this series led to the discovery of TAK-733. This was advanced to Phase I clinical studies for cancer treatment.
